Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.

Abstract: Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a ? structure in an aqueous solution at physiological pH and/or in the presence of cations.

Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.

Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.

Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.

Abstract: Described are lantibiotic-based compounds, pharmaceutical compositions comprising the same and use of the compounds and said compositions, for the treatment of microbial infection, for example Clostridium difficile or Micrococcus luteus infection. The lantibiotic-based compounds have antimicrobial activity and in comparison to one or more of actagardine, actagardine B, deoxyactagardine B and deoxyactagardine have retained activity or improved activity.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.

Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).

Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

Abstract: The present invention relates to a polypeptide that is capable of inhibiting transcription and expression of fatty acid synthase (FAS) and the polynucleotides encoding therefor, as well as the use thereof. Specifically, the present invention relates to a polypeptide that can inhibit the transcription and expression of FAS at the molecular level, the cellular level and in vivo, and can therefore prevent the overexpression of FAS. Said polypeptide and related peptidomimetics, including functional fragments or functional varieties thereof, and the genes encoding therefor, can be widely used in preventing and treating tumors such as liver cancer, and diseases closely related to the metabolism of fatty acid synthase, such as fatty liver and obesity.

Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.

Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.

Abstract: Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence comprising XAGXDXXTEXPXS (SEQ ID NO: 2), wherein X designates any amino acid, and (ii) a protein transduction domain (PTD) are provided, along with pharmaceutical compositions containing the fusion protein. The proteins can be used to treat Huntington's disease.

Abstract: The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer.

Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

Abstract: The present invention is directed to an active agent with contraceptive properties which corresponds to a peptide fragment of the Latrodectus mirabilisi's venom. The peptide generally includes the amino acid sequence of SEQ ID NO 2 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. Furthermore, a pharmaceutical contraceptive composition comprising the peptide fragment and one or more pharmaceutically acceptable vehicles is also described. The peptide fragment and pharmaceutical compositions are useful as a contraceptive and spermicide agent.

Abstract: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors important in disease progression, thus attenuating the disease.

Abstract: A peptide having antibacterial or anti-inflammatory activity and a pharmaceutical composition containing the same as an active ingredient are described. Also, a peptide having antibacterial or anti-inflammatory activity against dental bacteria, including periodontal pathogens, and bacteria causing atopic dermatitis, and a pharmaceutical composition containing the peptide as an active ingredient are described. The inventive peptide having antibacterial or anti-inflammatory activity can be used for the treatment of both dental infectious diseases, including periodontitis, and inflammations, including arthritis.

Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to RSP3 or Ash2L and that bind to Dpy-30.

Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.

Abstract: The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitrocell proliferation and for treatment of various diseases.

Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.

Abstract: The present invention provides reagents and methods for treating dental disease.

Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.

Abstract: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.

Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.

Abstract: A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis.

Abstract: This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.

Abstract: Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.

Abstract: Provided herein is tumor suppression composition and methods of making and using the same.

Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.

Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.

Abstract: The invention relates to ?-catenin targeting peptides comprising an ?-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive ?-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.

Abstract: The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells.

Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).

Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.

Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.

Abstract: Agonists of a non-proteolytically activated receptor can be used in methods for treating a disease or disorder in a subject. The methods comprise administering to the subject a therapeutically effective amount of an agonist, wherein the disease or disorder is scleroderma, macular degeneration, diabetic retinopathy, Huntington's disease, Parkinson's disease, closed head trauma, glaucoma, optic neuritis or allograft vasculopathy.

Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.

Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.

Abstract: TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling.

Abstract: Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (PRR) antagonist. In some instances the PRR antagonist is a polypeptide. The PRR antagonist can be a polypeptide having at least 70% identity to the amino acid sequence set forth in SEQ ID NO:2. Also disclosed are methods of decreasing proteinuria and methods of promoting wound healing by administering a PRR antagonist.

Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Abstract: The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub1-X1-D2-K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-T16-P17-N18-N19-X4-Sub2. The invention further relates to multimers comprising said peptides or peptide derivatives. Moreover, the invention provides a peptide or peptide derivative for use in the treatment of a disease. The peptide or peptide derivative may also be used in the screening for novel antimicrobial compounds.

Abstract: The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states.

Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.